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Abstract  
 
Digital healthcare is a rapidly growing healthcare sector. Its importance has been recognised at both 
national and international level, with the World Health Organisation recently publishing its first global 
strategy for digital health. The use of digital technology within cystic fibrosis (CF) has also increased. 
CF is a chronic, life limiting condition, in which the treatment burden is high and treatment regimens 
are not static.  Digital technologies present an opportunity to support the lives of people with cystic 
fibrosis. We included 59 articles and protocols in this state of the art review, relating to 48 studies 
from 1999 until 2019. This provides a comprehensive overview of the expansion and evolution of the 
use of digital technology. Technology has been used with the aim of increasing accessibility to 
healthcare, earlier detection of pulmonary exacerbations and objective electronic adherence 
monitoring. It may also be used to promote adherence and self-management through education, 
treatment management Apps and social media.  
 
Introduction  
The digital technology sector is a rapidly growing industry, with recent estimates suggesting digital 
technology is worth £184 billion to the UK economy1 and $1,351 billion to the US economy.2 Digital 
technology has become more accessible than ever before, especially amongst children and young 
people, with the Royal College of Paediatrics and Child Health describing this generation as “digital 
natives”; growing up surrounded by digital information. It is also an emerging field within the 
healthcare sector. It is widely used amongst the general population to track and promote health 
changing behaviours with devices such as exercise trackers and fitness Apps. Disease specific 
interventions are also emerging.  In chronic obstructive pulmonary disease and asthma, there has 
been a move towards the use of digital technologies in the ongoing monitoring of disease and 
adherence promotion. Strategies include text messaging reminders and web-based and mobile 
applications to monitor and record symptoms.3,4 Its importance has been recognised by the World 
Health Organisation who recently published its first global strategy for digital health. This brought 
together evidence for digital health interventions currently in use and provided recommendations for 
future development.5  
 
Cystic fibrosis (CF) has also seen the application of digital technologies. CF is an autosomal recessive, 
multisystem disorder. In the UK there are around 10,000 people living with the condition, of which 
40% are under the age of 16.6 In the US around 34,000 people have CF,7 with the predicted life 
expectancy of 46 years for those born in 2017.8 CF is caused by abnormal functioning of the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR), responsible for the transport of chloride and 
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 3 
regulating the movement of water and ions across epithelial surfaces. Based on the CF pig model, a 
defect in the CFTR protein may lead to abnormal mucous pH in the periciliary fluid and mucous stasis 
which is primarily responsible for the multisystem manifestations of CF.9,10 Specialist CF centres in 
conjunction with developments in treatments, improvements in antibiotic therapy, and better 
nutrition have improved outcomes for people with CF (pwCF).11 However, treatment regimens have 
become increasingly complex, with many patients prescribed daily airway clearance techniques 
(ACTs), exercise, inhaled and nebulised medications, pancreatic enzyme replacement (PERT) and 
dietary supplementation. Intravenous antibiotics are required for acute pulmonary infections, often 
more frequently as patients get older.  
 
Despite the complexity of CF therapies, much of the regimen can be completed in the patient’s home, 
allowing the integration of treatments into everyday routines, with regular monitoring from the CF 
team. However, treatments are tiring, time-consuming and burdensome; the average time spent on 
treatments for children in the UK is 137 minutes per day and 150 minutes in adults.12 In addition, the 
routines of adults and families of children with CF are not static; managing the condition is a dynamic 
process involving ongoing adaptation and readjustment.13 Managing treatments alongside daily life 
activities can therefore be challenging and restrictive. Digital technologies present an opportunity to 
support and improve the lives of pwCF. Indeed, pwCF and parents acknowledge the role of technology 
and there are a range of applications and platforms that have been designed by them for pwCF.  
The aim of this state of the art review is to provide comprehensive overview of the evolution of CF-
specific digital technologies and their effectiveness in the promotion of home monitoring, adherence 
or self-management in what is a rapidly changing area of medicine.  
Methods 
We conducted a systematic literature search of electronic databases and clinical trials registers from 
1/1/1999 to 14/02/2019. The protocol with full search strategies and inclusion criteria can be found 
at https://nottingham-repository.worktribe.com/output/2044553. Broad search criteria were used 
and full text, article abstracts, conference abstracts and trial protocols were considered for inclusion 
in order to increase sensitivity. Once duplicates were removed, a total of 1968 electronic search results 
were identified which were imported into Covidence14 and considered for inclusion. The search results 
were reviewed independently by two reviewers. We excluded 1,665 articles on title alone, leaving 303 
for full text screening, of which 51 articles met criteria for inclusion. Searches of clinical trials 
registered over the same time period identified 48 protocols, which following duplicate removal and 
screening, identified a further 8 studies. Once the final articles had been identified, data were 
independently extracted by both reviewers with results collated into MS Excel. We included 59 articles 
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 4 
and protocols (online table 1), relating to 48 studies. The general quality of the evidence was low; 
mainly consisting of small interventional and before after studies with only three full text randomised-
control trials (RCTs) and one systematic review. Figure 1 highlights the expansion of technology over 
the last twenty years. Although for the purposes of this review technology has been assessed for its 
role within either home monitoring, measuring adherence or self-management we recognise that in 
practice these are often inter-related concepts in relation to CF.  
 
Digital technology used for home monitoring  
Increasing accessibility to healthcare 
Centralisation of care means that many patients do not live in close proximity to their CF centre which 
potentially becomes a barrier to accessing healthcare. Therefore, digital technology has been explored 
as an option for remote delivery of care. Videoconferencing has been used for delivery of routine 
appointments, annual assessments and multidisciplinary team (MDT) discussions,15 with more recent 
studies also able to share imaging, educational slides, lung function and microbiology results. Although 
there was no significant difference in Forced Expiratory Volume in one second (FEV1) results reported 
with teleconferencing, one study described positive patient satisfaction and 63% felt it was as good as 
a face to face review.16 It has also been used more widely for delivering mental health services to pwCF 
online.17 These studies again were small interventional studies and larger RCTs are required to fully 
assess the impact on telehealthcare in remote delivery of care. An ongoing RCT, VIRTUAL-CF is using 
videoconferencing to the CF MDT with remote spirometry and oxygen saturation measurements for 
patients receiving intravenous antibiotics in the community. It is assessing whether this approach 
promotes health-related quality of life compared to standard community intravenous antibiotics 
care.18 
 
Home monitoring for early detection of pulmonary exacerbations 
Despite life expectancy improving, the majority of deaths in CF are still attributable to respiratory 
failure secondary to recurrent pulmonary exacerbations. Exacerbations also contribute to morbidity; 
worsening CF related diabetes and reducing health-related quality of life.19-21 Therefore, the use of 
digital technology has been evaluated to determine if it can lead to the earlier detection of 
exacerbations and subsequently reduce the rate of respiratory decline. One of the first uses of digital 
technology in this context was in the 1980s for home monitoring of respiratory symptoms and lung 
function.22 This, along with other earlier studies, used a combination of home spirometry, measuring 
physical parameters such as heart rate and oxygen saturations, blood glucose levels and respiratory 
symptom scoring with the results collated and sent via modem internet to the CF centre.23  In more 
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 5 
recent work, advances in technology have allowed streamlining of data transmission via Wifi or 
Bluetooth. A small non-randomised interventional study showed promising results in FEV1 status. Data 
collected from a Spirotel™ device (Medical International Research, Rome, Italy) were sent via email to 
the CF centre, with patients contacted if they met intervention criteria for an exacerbation based on 
FEV1 decline or oxygen saturations.24 A significantly smaller decline in annual FEV1 status was noted in 
the telehealth group over a 4.5 year period. However, these results were not subsequently supported 
by a large multi-centre RCT, the Early Intervention in Cystic Fibrosis Exacerbation (eICE) trial.25,26 Using 
twice weekly home spirometry (Viasys AM2 device, CareFusion, California, USA) and respiratory 
symptom scoring, patients were contacted by the CF team if a reduction in FEV1 greater than ten 
percent or an increase in respiratory symptoms was seen. The early intervention group had a shorter 
time to first exacerbation and more exacerbation treatments compared to the control group, however 
this was not associated with a slower FEV1 decline. The trial was stopped early for futility, as 
completing the trial was unlikely to show a difference in primary end point.27 
 
However, the eICE study highlights the issue of adherence. In a condition where treatment burden is 
already high, home monitoring adds an additional task for the patient to complete. Home monitoring 
studies have required data entry from once a month to three times a week.28,29 Adherence to 
telemonitoring in the eICE trial over 52 weeks was suboptimal; 50% of patients transmitted data once 
per week and only 19% twice per week as per the protocol, with an increased treatment burden score 
in the early intervention telemonitoring group.26 
 
 
Ongoing studies 
Current studies are assessing the use of smartphone applications for the earlier recognition of 
exacerbations through changes in respiratory symptoms. They hope to establish whether having 
monitoring which is less restrictive and more mobile would improve adherence and therefore 
outcomes.30,31 Unfortunately, preliminary data from  RCT (ACTRN12615000599572) suggests that the 
use of a smartphone for symptom reporting had no effect on the number of courses of antibiotics or 
days of antibiotic treatment, with full results awaited.32 
 
Digital technology for monitoring and promoting adherence and exercise 
 
 Home monitoring for supporting adherence 
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 6 
Adherence monitoring enables treatment guidance and allows clinicians to differentiate if changes in 
a patient’s condition are related to disease progression, attributable to poor adherence or a 
combination of the two. The impact of home monitoring on treatment adherence in adolescents and 
young adults has been explored in a before and after study using once weekly home monitoring and 
adherence monitoring using medication prescription refill data to calculate the medication possession 
ratio (MPR).33  In comparison to Lechtzin’s eICE study, adherence to weekly spirometry monitoring 
was 59% which may reflect the impact of parental supervision in this population group. Less frequent 
monitoring may have lessened the treatment burden to patients. There was a small associated overall 
increase in medication adherence; MPR was 60% in the year prior to study enrolment, and 65% during 
the 12 month study period (p=0.038). These authors found no change in the number of exacerbations 
or FEV1 decline between groups across the study period.33 
 
 
Digital technologies for adherence  
Self-monitoring also helps patients better understand and self-manage their condition.  However, self-
reporting of adherence is notoriously inaccurate and so alternative ways for adherence monitoring 
are being pursued. Prescription refill data and MPR is a valid and inexpensive way of monitoring 
adherence however, this is still prone to inaccuracies, as it is based on the assumption that all of the 
medications refilled are always taken.33 Hence digital technologies are being developed to more 
accurately record treatment adherence.34 
One small intervention study compared self versus digital electronic adherence recording of a high-
frequency chest wall compression vest (Vest System, Hill-Rom, Indiana, USA). Although the results 
showed a high variability in self-reporting, it supported the view that patients over-estimate treatment 
duration; by 127% in adults and 26% in parents of children wCF over a 2 week period. Overall average 
treatment adherence was 69%.35 
An established digital technology for adherence monitoring in CF is the data logging nebuliser device 
which combines routine nebuliser treatment with accurate adherence logging, via an electronic data 
capture facility. This gives an insight into how often and how long treatments are taking to build a 
picture of adherence. One such device is the I-NebTM (Respironics, Chichester, UK). It is an adaptive 
aerosol delivery system which adapts medication delivery to the patient’s breathing pattern, 
delivering only during inspiration.36,37 It also provides patients with visual and audio feedback whilst 
they undertake their treatments. Its data capturing facility allows trends to be identified. For example: 
although one study found adherence was maintained between 60-70% over one year, diurnal 
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 7 
variation was also noted; evening 70% vs 58% morning (p=0.012).36 This allows for more realistic joint 
goal setting and changes to treatments based on the results.35,36 However, this device is currently only 
available to a subset of patients prescribed PromixinTM (colistimethate sodium, Profile Therapeutics 
plc, West Sussex, UK) and although data logging devices may provide useful information to the CF 
team regarding adherence, some patients may find this level of monitoring intrusive.  
Insight OnlineTM (Respironics, Chichester, UK) has been developed to be used alongside the I-NebTM. 
It is a home monitoring telehealth interface, where patients upload data from the I-NebTM to a server. 
The data are then analysed and presented for patients and clinicians to view. Patients are encouraged 
to set treatment targets, against which they can self-monitor their progress. Data presented from a 
small intervention study had mixed results. This showed that for the patients who did engage it 
improved adherence, however over 50% of the participants failed to upload regularly.38 This result 
again raises the issue of increased treatment burden on patients, and that CF teams’ perceived benefit 
of technology may not be shared by all patients.   
Digital Technologies for exercise 
The video gaming industry is a continuously growing global industry accessed by 64% of the US 
population. Of those using game consoles, 76% played for at least 3 hours a week with the majority 
using it for significantly longer.39 Exercise is a key treatment in CF and, given the popularity of gaming 
technology, incorporating exercise through gaming has been explored as a strategy to help people to 
engage and self-monitor exercise. There have been small interventional studies using games consoles 
for promotion of home-based exercise.40 A RCT used the Nintendo Wii EA Sports Active 2 to deliver a 
six week training programme of 30-60 minute sessions, five days a week, monitored by a virtual 
personal trainer, with participants followed up for 12 months following the intervention.41,42 
Unfortunately this did not support the use of video gaming. Although both control and intervention 
groups showed a significant difference between physical parameters pre and post study, there was no 
difference between groups. In addition, although short term adherence was good, with 95% adherent 
at 6 weeks, this was not sustained and reduced to 35% using the game twice a week by 12 months, 
with 65% not using it at all.41 A potential reason is that if games are played frequently over an extended 
time period there is an element of monotony, similar to treatment regimens.   
Fitness trackers have been used within the general population for some time to promote exercise, 
with CF-specific trials focused mainly from 2017 onwards. A RCT by Bishay compared a fitness tracker 
with a personalised exercise prescription and social media platform to exercise prescription alone over 
a 12 month period.43 This study did not support the use of fitness trackers in CF with no significant 
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 8 
difference between the two groups in terms of exercise tolerance, pulmonary function or patient 
reported outcomes. 
There are other examples of social media and web-based platforms for exercise promotion. A small 
interventional pilot study used a closed Facebook group to promote a 30 day exercise challenge to 
increase daily exercise.44 Pactster in the UK (developed with the CF Trust) provided online exercise 
classes and included instructors who have CF.45 “CFYOGI” in the USA46 is an exercise web platform co-
founded by a pwCF and a parent of children with CF in partnership with Social Good Fund. It includes 
livestreamed and recorded fitness videos led by instructors with CF and has community features 
allowing patients to share progress and fitness goals while avoiding cross-infection risks. 
 
Ongoing studies  
The development of data-tracking nebulisers has led to the development of CFHealthHub 
observatory,47 a large scale data observatory which aims to recruit 6,000 pwCF over the period 2017-
2021 and collect observational data using patients’ data tracking nebulisers. In addition, it will be used 
as part of a large multicentre RCT (ISRCTN55504164)48 which will combine the use of data captured 
from data tracking nebulisers with behavioural change interventions available via a web portal, 
CFHealthHub. Data is available to be viewed by both clinicians and pwCF, with the primary outcome 
of the study being number of exacerbations. Secondly, a non-randomised cross over study 
(NCT02700243) is exploring the use of video games in improving adherence to ACTs using a positive 
expiratory pressure (PEP) device. Electronic versus self-reporting of adherence will be monitored over 
a 4 month period, following which a video game will be integrated into the PEP device operated by 
the patient performing their therapy correctly. Primary outcome is adherence to therapy, with change 
to pulmonary function a secondary outcome.49  
 
There are several ongoing studies in relation to exercise.50 ACTIVATE-CF,51 is using pedometers and 
daily web-based logging of exercise activities in addition to the standard care of 3 monthly counselling 
sessions to promote physical activity. Patients are encouraged to exercise 3 hours a week, with FEV1 
status being the primary outcome. Another RCT (NCT03672058) combines the use of FitbitTM exercise 
trackers (Fitbit, Inc. California, USA) with an online activity monitoring system (Fitabase) and 
personalised feedback on activity levels and progress, compared to the use of a Fitbit alone on steps 
per day and FEV1 status.52 Finally, project Fizzyo combines their use with ACT devices to assess activity 
levels, with chipped ACT devices used to capture daily adherence data.53 Data transmission appears 
more streamlined compared to other studies, with the results sent automatically once the ACT device 
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 9 
is synchronised with a tablet computer. In addition, computer games have been developed in 
conjunction with patients to be used at different intervals within the study to assess the impact of 
gaming on adherence.53 
 
 
Digital technology for education and self-management  
Self-management is key to successful management of chronic conditions such as CF. Self-management 
has been described as the process of helping patients and their families to choose, monitor and adjust 
their treatment requirements in relation to their condition and the effect it has on their lives.54  
 
Education  
Multiple digital technology platforms have been explored to promote self-management through 
education delivered as either self-guided sessions or mentor-supported individual or group web-based 
sessions. Whilst they may provide educational opportunities for participants, the self-management 
education and digital technologies themselves have had limited success, so far, in relation to patient 
outcomes. This is in keeping with a Cochrane review that suggested self-management education in CF 
could provide limited positive change for a small number of self-management behaviours.54  
 
Early education strategies explored education delivery via a CD-Rom, combining a computer game 
with education.55 Several platforms have since been developed. Web based education has increased 
in popularity, and the use of smartphones and Apps has been developed.56 CFfone provided access to 
the CFfone website via a smartphone, which contained educational materials and social support 
through inspirational stories and communication with peers in an online community.57 The BeInCharge 
study for parents of children with CF combined an education programme on dietary education, 
personalised calorie intake goals and behaviour techniques with a daily diet tracker App. Use of the 
App resulted in no significant increase in weight gain in the intervention group and indeed the App 
was less successful in achieving weight gain compared to the face-to face delivery used previously.58  
 
Individual education delivery for both children and adults guided by a mentor or physio has been 
explored. Patients in a small RCT, with two intervention treatment arms, used an online mentor-
guided self-efficacy programme with or without an App to monitor their symptoms and quality of life, 
compared to the control group.59 Results were limited by the small sample size although patients 
reported being confident in using digital technology. An increase in self-efficacy was seen across the 
intervention groups; however, this was similar in both groups with and without the use of the App. 
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 10 
Similarly, group sessions in CF have been limited to small interventional trials.60 Results of larger 
studies are required, one of which has recently been completed.61 This delivered 6 online modules 
relating to nutrition, medications and respiratory and liver disease. Patients also completed tasks and 
had access to videos of patients sharing their experiences. Preliminary data at 6 months show mixed 
results, with adherence data awaited. Significant improvements in body mass index and ADE vitamin 
levels were seen, however this did not translate to a reduction in lung function decline.61,62 
 
Ongoing studies using education  
Two large RCTs addressing this issue are due to be completed in 2019. Project UPLIFT provides group 
web-based education and intervention programme focusing on improving anxiety and depression in 
pwCF.63  Adherence is a secondary outcome. It focuses on education on depression and CF; coping 
strategies such as cognitive behavioural therapy and mindfulness; and relaxation techniques. An 
Australian project CyFiT, 64 encompasses several aspects of digital healthcare delivery. It combines the 
delivery of outpatient physiotherapy via videoconferencing, with additional multimedia and 
educational features. Participants are also given an activity tracker to record sleep and physiological 
parameters to guide exercise prescriptions and the telehealth sessions. The primary outcome is 
pulmonary function and the comparator is standard physiotherapy.  Finally, a pilot study for a RCT 
(NCT03637504) plans to evaluate the feasibility of MedActionPlanTM (MedActionPlan, Peapack, USA); 
a web-based medication management App which uses education about treatment regimens to 
encourage self-management and adherence. Adherence is assessed using eTrack nebulisers and 
AdhereTechTM pill bottles (AdhereTech, New York, USA).65   
 
Digital technology for self-management of treatments  
Digital Apps are being used in a variety of contexts within CF including symptom monitoring, education 
and diet tracking. A newer area of interest is the development CF-specific Apps to help manage 
treatment regimens. “Genia” is a Swedish based treatment management App developed by a father 
and his daughter, who has CF,65 which allows pwCF to track their condition as well as providing the 
option to share information with care teams about symptoms, daily activities and medications, as well 
as sharing updates with family and friends.  
Ongoing Studies 
In the context of pancreatic insufficiency, smartphone Apps are under development which will be 
capable of calculating patient specific PERT requirements.66-68 MyCyFAPP is a multicentre, 
multidisciplinary development currently being tested which aims to allow patients to better self-
manage their PERT and nutrition. Importantly, parents and patients of various ages were involved in 
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the development phase as part of interviews and focus groups. The protocol describes a number of 
expected features of the App including education through games, food and symptom scoring records 
and a handbook containing nutritional information, in addition to calculating optimal PERT dosing. 
These data are also accessible to clinicians with alerts for suboptimal treatment, with the aim of 
promoting more focused and realistic goal setting at follow ups.68 
 
The use of social media for self-management in cystic fibrosis   
Social support is known to improve self-management and therefore the use of social media to provide 
social support has been explored, although CF-specific research is limited. A thematic analysis 
undertaken on a CF charity website message board found that online support groups seem to 
supplement professional support in relation to self-management and self-esteem.69 Social media has 
also been incorporated into projects such as CFfone (described previously).  No larger CF-specific 
studies were identified. 
 
Conclusion  
Digital technology is a growing industry. We have highlighted the expansion and evolution of its use 
in CF over the last 20 years for supporting home monitoring, adherence and self-management. Despite 
the large number of articles, most were small pilot and intervention studies without comparators and 
there were very few full text RCTs. Although ongoing studies may yield some positive results, the 
majority so far have shown limited evidence to support the use of digital technology. An area of 
promise was electronic monitoring of adherence via data logging nebulisers to accurately capture 
adherence data. However, this does not address barriers to adherence. In addition, a potentially 
exciting area of development is the use of digital technology to assist in the self-management of 
medications, such as Apps providing patient-specific PERT dosing information. Future evaluation of 
the role of digital technology in CF will require well designed, adequately powered RCTs. Developers 
should be mindful that, in a condition where there is already a significant treatment burden, patients 
must find these technologies acceptable and sustainable. The benefits of digital technology must be 
carefully balanced against the investment of time needed to use them. Patient involvement in the 
design process is key. Furthermore, the benefits of treatment should be of benefit to the patient as 
well as the CF team.  
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Page 18 of 28
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Author and 
Year 
Study and article 
type 
Population and 
patient number 
Intervention 
 
Comparator 
 
Outcome 
 
Summary of findings 
 
Grade and Description  
Home Monitoring  
 
 
Increasing accessibility to healthcare  
Appiah-Kubi 
201215 
 
 
 
Descriptive 
Conference 
abstract 
 
 
Adults wCF 
71 patients 
 
 
 
Monthly videoconferencing session to main 
CF centre.  Blood tests taken locally and the 
results faxed to the centre prior to session.  
 
 
No comparator 
 
 
 
 
Improve patient care 
and education. Cost 
 
 
 
Improved patient care, reduced patient 
costs and improved inter-professional 
collaboration.  Used for routine clinics, 
medication explanations and to treat 
patients on IV antibiotics.  
Grade: Very low  
All three studies 
contributing data to this 
outcome were small and 
observational in design. 
Two of the papers were 
only available as an abstract 
and one of the studies had 
no comparator. The quality 
of the evidence for this 
outcome was downgraded 
accordingly.  
Becerra 201717 
 
 
 
 
Observational 
cohort study 
Conference 
abstract 
 
 
PwCF with mental 
health symptoms 
10 patients  
 
 
 
Telehealth interventions accessed by the 
patient in their home on relapse prevention, 
crisis management, CBT, emotional 
wellness, mental health coordination with 
an outside provider, assessment and 
linkage. 
Not specified 
 
 
 
 
 
Emotional functioning; 
mental health symptoms 
 
 
 
 
Telehealth improved how patients 
assessed their emotional functioning 
and assisted them with overcoming 
negative thinking patterns and 
improved their usage of coping skills.   
 
Lester 201616 
 
 
 
 
 
Observational 
intervention study 
Conference 
abstract 
 
 
Adults wCF  
29 patients 
 
 
 
 
Annual assessment delivered via 
videoconferencing with physio input, and 
shown educational slides, physical 
parameter trends and reports over 5 years. 
  
 
Usual care: in 
clinic  
 
 
 
 
Primary: improve 
understanding of ACT  
Secondary: how TM 
compared to face to 
face, and would they 
participate in future  
There was no improvement in FEV1 % 
after the TM call. Patients were 
satisfied with TM and would participate 
in other TM education opportunities 
(95%). 63% thought was as good as face 
to face.  
Bella 201775 
 
 
 
 
Observational 
cohort study 
Conference 
abstract 
 
PwCF  
50 patients 
 
 
 
Various technologies to deliver home 
telemedicine over a 15 year period. FEV1 
monitored at home.  
 
 
Unclear 
 
 
 
 
FEV1; adherence; 
pulmonary relapse 
 
 
 
36% drop out, 68% of which was due to 
poor adherence. Benefits of using 
telemedicine identified were a better 
doctor-patient relationship and 
increased QoL.  
 
Ongoing studies 
NCT03069651 
201718 
 
 
 
 
 
RCT  
Protocol 
 
 
 
 
 
Adults wCF 
requiring 
community-
delivered IV 
antibiotics  
100 patients 
 
VIRTUAL-CF: Community IV antibiotics. 
Patients perform spirometry and pulse 
oximetry twice weekly during 
videoconferencing with the CF MDT with 
community CF nurse if required as usual.  
 
 
Usual care: 
MDT input at 
beginning of 
antibiotic 
course with CF 
nurse visit if 
required.  
Primary: health related 
QoL 
Secondary: patient 
satisfaction, lung 
function, weight, 
economics  
 
Ongoing trial Dec 2016 - Dec 2019.  
 
 
 
 
 
 
Ongoing study 
Home monitoring for early detection of pulmonary exacerbations  
Bell71 
 
 
Editorial review 
Full text 
 
PwCF (14yrs+) FEV1 
>25% 
320 patients 
As per eICE trial 
 
 
As per eICE trial 
 
  
As per eICE trial 
 
 
Editorial review of eICE trial by Lectzin. 
Poor adherence to trial discussed.  
 
 
Cox 201270 
 
 
 
 
 
 
 
 
 
 
 
Systematic review  
Full text 
 
 
 
 
 
 
 
 
 
 
PwCF 
8 studies  
 
 
 
 
 
 
 
 
 
 
Telehealth to monitor health symptoms, 
adherence or provide therapy via some 
form of user interface, i.e telephone, 
videoconferencing or electronic diary. 
 
 
 
 
 
 
 
 
Different for 
each study 
 
 
 
 
 
 
 
 
 
 
Monitor symptoms, 
assess adherence to 
prescribed therapies or 
provide therapy via 
some form of user 
interface 
 
 
 
 
 
 
 
Patients were confident in their ability 
to use the technology. However, in 
many studies participants failed to 
provide data at the time points 
required. Insufficient evidence to reach 
a firm conclusion about the benefits of 
telehealth in PwCF. Most studies were 
small feasibility trials with limited 
external validity. 
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Frost 201772 
 
 
 
 
 
 
Intervention study  
Conference 
abstract  
 
 
 
 
Inpatient adults wCF  
36 patient 
 
 
 
 
 
Step counting via a smartphone activity 
tracker. Retrospective review of participants 
recorded steps for three seven day periods 
1) before discharge 2) week before 
admission 3) a week when clinically stable 
 
 
Comparison 
between the 
time periods 
 
 
 
 
Whether using a 
smartphone step 
counter App can detect 
changes in health status  
 
 
 
Those with better lung function trended 
towards increased steps. Step-count 
was significantly lower when an 
inpatient than when clinically stable 
(1292 vs. 3104) and significant 
decreased in the 5 days immediately 
prior to admission. 
 
Fischer 200323 
 
 
 
 
 
 
RCT 
Conference 
abstract  
 
 
 
 
Adult wCF 
51 patients 
 
 
 
 
 
Twice weekly home spirometry, oxygen 
saturations, heart rate, blood glucose and 
QoL. Data transmitted via a modem 
connection to the CF centre to detect onset 
of deterioration and PE. Patients can follow 
their own lung function at home.  
 
Regular care: 3 
monthly visits 
in clinic  
 
 
 
 
Hospitalisations, drug 
prescription rate; 
periods of disability; 
days out of work; lung 
function. 
 
 
Ongoing study at abstract submission:  
too early to report lung function but 
trend toward improved motivation and 
lung function in telemedicine group. 
Some patients did not tolerate the 
frequent FEV1 measurements. No follow 
up results identified.  
 
 
Grade: Low  
Although two of the studies 
were RCTs, only one of 
these was published as a 
full paper. The quality of the 
evidence has been 
downgraded due to small 
numbers of participants in 
all but the full RCT and 
heterogeneity in the 
findings. 
Lechtzin 
201721,26,27,73,74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RCT  
Full text 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PwCF (14yrs+) FEV1 
>25%. 267 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EI arm (Home monitoring): Visay AM2 
spirometry which recorded spirometry and 
8 questions from the CFRSD twice weekly. 
Results uploaded to central database and 
contacted if FEV1 decreased >10%, or 
declined in symptoms  
 
 
 
 
 
 
 
 
 
 
 
Usual care 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 week change in FEV1; 
CFQ-R; CFRSD; FEV1 % 
predicted; FVC (L); 
FEF25-75; Time to first 
PE; time from end of 
first PE to start of 
subsequent PE; Number 
of hopsitailisations and 
days; prevalence of 
P.aeruginosa; 
prevalence of staph 
aureus; protocol burden. 
 
 
 
 
 
Interim data (2014): 35% patients were 
>80% adherent.76% used device at 
least 1x week74 
Interim data (2015): 74% patients 
required alarm at 5 days to remind 
them to submit data,  51% were 
compliant of their weekly data 
transmission 20% managed 2 x week73 
Final article (2017): More PE and time 
to first PE shorter in EI group, but didn't 
result in slower decline in lung function 
with no difference in FEV1 change. Once 
weekly data transmission 50%; 19% 
twice weekly. No change in 
Pseudomonas compared to baselines. 
The intervention was associated with an 
increased burden.22  
Murgia 2012 
and 201524,75 
 
 
 
 
Non-randomised 
controlled 
intervention study  
Full text 
 
 
PwCF  
32 patients 
 
 
 
 
Telehomecare: twice weekly remote 
transmission data via Spirotel (Home Vivitel 
Control Service spirometry) pulmonary 
symptoms and overnight pulse oximetry. 
Used as an adjunct to standard therapy.  
 
Standard 
therapy 
 
 
 
 
FEV1 reduction >10%; 
worsening of symptoms; 
nocturnal pulse 
oximetry; oxygen 
saturations 
 
Telemedicine group showed a 
significantly lower decline in FEV1. 
Patients accepted the home 
telemonitoring, high number of daily 
responses and increased data 
transmission over time. 
Van Horck 
201729 
 
 
 
 
 
 
 
 
Multicentre, 
observation 
cohort study  
Full text 
 
 
 
 
 
 
PwCF (5 -19 years) 
49 patients 
 
 
 
 
 
 
 
 
Home spirometry and respiratory symptom  
monitoring via Handheld Jaeger home 
monitor three times a week, with data 
transfer to web-based portal once a week.   
Patients split into exacerbation (E=28 
patients) and non-exacerbation (NE=9 
patient) groups.  
 
 
 
No comparator 
 
 
 
 
 
 
 
 
 
Primary outcome: 
detection of PE FEV1 (% 
predicted), RSS, 
adherence to home 
monitor 
 
 
 
 
 
Increase in the RSS in the 2 weeks 
before a PE (p=0.051). No deterioration 
in FEV1 % predicted in the 4 weeks 
before a PE. Mean FEV1 % predicted and 
mean RSS of four weeks to one week 
before an PE resulted in good sensitivity 
92.9% (CI 75.0–98.8%) and specificity 
88.9% (CI50.7–99.4%) to predict a PE. 
54% of the children had good to 
optimal adherence 
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Wall 201128 
 
 
 
 
 
Intervention study 
Conference 
abstract 
 
 
 
PwCF (7-17 years) 
>120 miles from CF 
centre 
10 patients 
 
 
Minimum monthly home spirometry, FEV1 
and 6 likert questions relating to respiratory 
symptoms via internet. Reponses reviewed 
by CF nurse within 24 hours and contacted 
via phone 
 
No comparator 
 
 
 
 
 
Responses leading to an 
intervention (starting 
oral abx, hospitalisation, 
call to come to clinic or 
advice). Number of 
interventions required. 
40% of encounters led to an 
intervention. Patients were more likely 
to submit data when they experience 
symptoms. Major barriers were 
forgetfulness and denial 
 
Ongoing studies 
NCT02122289 
201431 
 
 
RCT  
Protocol 
 
 
PwCF (14 - 25 years) 
45 patients 
 
 
Weekly symptom scoring questionnaire via 
smartphone over 6 months. Creates an alert 
to identify a possible PE 
 
No smartphone 
App 
 
Primary: frequency of PE 
Secondary: user 
satisfaction of device 
and compliance  
2014 - 2016. No results found.  
 
 
 
Ongoing studies 
ACTRN12615-
000599572 
Wood 201830 
 
 
RCT  
Conference 
abstract 
 
 
adults wCF  
60 patients 
 
 
 
Smartphone app used weekly for symptoms 
reporting to CF team. Contacted by CF nurse 
if symptomatic for a PE  
 
 
No App 
 
 
 
Whether an App can 
early detect an PE, 
affects number of 
courses and days of IV 
abx. 
The preliminary results had no effect on 
number of days or courses of 
antibiotics.  
 
 
Digital technology for monitoring and promoting adherence and exercise 
 
Home monitoring for supporting adherence  
Grade : very low  
 
All studies had small 
numbers of participants and 
no comparator group 
therefore the quality of 
evidence has been 
downgraded. 
Shakkottai 
201833,78  
 
 
 
 
 
 
 
 
 
 
 
Pilot study and 
prospective 
interventional 
study 
Full text 
 
 
 
 
 
 
 
 
PwCF (12-21 years) 
39 patients 
 
 
 
 
 
 
 
 
 
 
 
SpiroPDTM personal spirometer to measure 
lung function at home (1x week) and daily 
personal medication reminders. Prescription 
refill data collected. 
 
 
 
 
 
 
 
 
 
Measurements 
from the year 
preceding the 
study 
 
 
 
 
 
 
 
 
 
Adherence; perception 
of treatment burden via 
CFQ-R; PFTs; BMI; 
frequency of 
exacerbations requiring 
IV or oral antibiotics 
 
 
 
 
 
 
 
Pilot study completed to test feasibility 
of equipment being used for the first 
time in this age group.  
Mean adherence to weekly spirometry 
59.47%. Mean treatment burden: 68 at 
enrolment and 66 at study completion 
(P = 0.14). 30% had greater than 80% 
adherence.  Medication adherence 
overall increased from 60% to 65% 
(p=0.038). No statistically significance in 
adherence to individual oral and IV 
medications, exacerbations or FEV1 
decline 
Digital technologies for adherence 
Thorton 201438 
 
 
 
 
 
 
 
 
Intervention 
study 
Conference 
abstract 
 
 
 
 
 
PwCF (6 - 17 years)  
28 patients 
 
 
 
 
 
 
 
I-neb Insight onlineTM: Record iNeb and 
symptom monitoring twice weekly and 
upload to Insight online. Patients receive 
prompts if fail to upload data regularly.  
 
 
 
 
 
No comparator 
 
 
 
 
 
 
 
 
If telehealth system 
(iNeb and Insight Online) 
promotes adherence to 
nebulised treatment  
 
 
 
 
 
Group 1: independently uploaded, 
group 2: uploaded with prompts, group 
3: failed to upload despite prompts.  
Group 1: adherence maintained >85%. 
Group 2: 38% baseline - 111% at 2 
months Group 3: 71% baseline - 7% 
change at 2 months. on iNeb 
downloads. >50% failed to upload 
regularly.  
McNamara 
200936 
 
 
 
Retrospective 
observational 
study. 
Full text 
 
PwCF  (2–15 years) 
with P. Aeruginosa 
infection 
48 patients 
 
Use of I-nebTM AAD with data logging 
facility.  
 
 
 
No comparator 
 
 
 
 
Treatment episodes. 
Adherence  
 
 
 
Overall monthly adherence to nebulised 
therapy was 60-70% over one year. 
Considerable variation; evening better 
than morning adherence (75% vs 58%: 
p=0.012). 
Mikesell 201735 
 
 
 
 
Interventional 
study  
Full text 
 
 
PwCF (6- 24 years) 
using HFCWC 
equipment  
85 patients 
 
The Vest System model 105TM. Records data 
on time, duration of use, frequency of 
compressions and compression pressure 
intensity with data downloaded every 30 
days.  
No comparator 
although they 
did compare 
results for 
those who had 
Compare self-reported 
to objective adherence 
measurements via 
HFCWC vest.  
How adherence 
Average adherence was 69%; highest in 
children and those assisted with 
treatment (82%). Overestimation of 
therapy duration by adults (127%), 
26.3% by parents.  Average daily 
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3 cohorts: <13 years, 13-18 years, 19+ years 
 
 
 
an exacerbation 
with those who 
did not. 
correlates to baseline 
pulmonary functions 
and exacerbations 
therapy time and adherence had 
significant positive associations with 
baseline FEV1 percent of predicted and 
negative associations with PE.  
Thorton 201334 
 
 
 
 
 
 
 
 
Intervention 
study  
Conference 
abstract  
 
 
 
 
 
PwCF (5 - 16 years)  
15 patients, 
 
 
 
 
 
 
 
Self-reporting vs iNeb reporting of 
adherence to nebulisers. Use of Insight 
Online telehealth home monitoring.  
 
 
 
 
 
 
No comparator 
 
 
 
 
 
 
 
 
Self-perceived vs 
electronic adherence 
(iNeb); Determine if the 
feedback from Insight 
Online optimises 
adherence 
 
 
 
Inaccurate self-reported adherence; 6 
patients within 10% accuracy of actual 
vs perceived adherence. When Insight 
Online used with the iNeb it maintained 
adherence in 3 out 4 children with 
adherence already above 90%. 6/11 
children who’s adherence <90% 
improved by a median of 22.3% over 4 
weeks.  
Spencer 201277 
 
 
 
 
Observational 
intervention 
study 
Conference 
abstract 
PwCF 
49 patients 
 
 
 
I-NebTM ADD with data logging facility, with 
Insight Online, a telemedicine patient 
management system 
 
 
No comparator 
 
 
 
 
Resolution of treatment 
issues; adherence; 
compliance; treatment 
time 
 
I-neb Insight Online adherence 69.4%. 
Mean TBM treatment time of 4.9 min, 
and a mean TIM treatment time of 2.9 
min.  
 
 
Digital technologies for exercise  
Aquino 200682   RCT cross-over 
design  
Conference 
abstract  
PwCF (7 - 29 years) 
13 patients 
Physical exercise via PlayStation 2 - Eye 
Toy1. 4 minutes game followed by 3.5 
minute break with 3 bouts of cough and 
sputum expectoration.  
4 minutes PEP 
mask followed 
by 3.5 minutes 
break with 3 
bouts of cough 
and sputum 
expectoration. 
weight of sputum; 
SaO2%; VAS test 
No significant difference in sputum 
production, resting saturations, peak 
oxygen desaturations between groups. 
Exercise as effective as PEP 
 
Bishay 201843   RCT  
Conference 
abstract 
Adults wCF  
40 patients 
A personalised exercise prescription 
provided by a physical therapist plus use of 
a wearable fitness tracker integrated with a 
social media platform.  
Exercise 
prescription 
alone  
Primary: mean level 
completed on a GXT 
after 12 months  
Secondary:  change in 
GXT and FEV1, mean 
FEV1 at one year, anxiety 
and depression  
Provision of a fitness tracker with an 
exercise prescription did not result in 
significant improvements in exercise 
tolerance, pulmonary function or 
patient reported outcomes compared 
to exercise alone. The results did not 
support routine use of fitness trackers 
in adults with CF. 
Grade: Moderate  
 
The evidence for this 
outcome came from two 
RCTs which had small 
numbers of participants but 
compared the digital  
technology with usual 
exercise prescription. 
Del Corral 
201841,42,83 
Pilot study and 
RCT  
Full text 
PwCF (7 - 18 years) 
Clinically stable  
41 patients 
6 week home training programme (30-60 
minute sessions, 5 days a week using a 
Nintendo WiiTM with the game EA sports 
active 2, supervised by a virtual personal 
trainer. Training load increased weekly, 
along with weekly phone calls from physio. 
After the training programme, participants 
were asked to continue the program for a 
12 month follow up period. 
Normal care: 
usual exercise 
programme 
without 
Nintento WiiTM 
Primary: MSWT; 
Secondary: 6MWT; 
Horizontal jump test; 
medicine ball throw; 
hand grip; spanish 
version of the CFQ-R, 
HRQoL 
Pilot study: improved exercise tolerance 
on 6 min walk test and shuttle test. 
Respiratory symptoms and physical 
tendency domains were statistically 
significant. No significant difference 
between the dyspnoea and fatigue 
perception.63   
RCT: Significant between-group 
differences in exercise capacity before 
versus after intervention. Good short 
term adherence (95%), Poor overall 
adherence at 12 months; 35% exercised 
2 days a week, 65% patients didn’t use 
Wii for exercise.62 
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Smith 201544  Observational 
intervention pilot 
study  
Conference 
abstract  
PwCF 
10 patients  
Facebook challenge: Increasing the daily 
number of squats, press ups and sit ups. 
Participants encouraged to post their 
progress on social media 
 
No comparator 
  
Increase motivation to 
exercise  
Half the patients found it maintained 
their motivation to exercise.  
Grade: Very Low  
 
Small study with  no 
comparator group  
Ongoing studies  
ACTRN126130-
00929707201379  
 
 
 
 
 
RCT  
Protocol 
 
 
 
 
 
PwCF 4-17 years) 
36 patients 
 
 
 
 
 
PEP PT: PEP with additional features 
including reminder alarm, screen display 
showing pressure curve to achieve ideal 
technique with gaming features, and point 
scoring which can be redeemed for rewards. 
Information stored to be used with 
clinicians to guide consultations.  
PEP device that 
measures 
adherence and 
technique, 
without 
feedback 
function  
Primary: adherence to 
PEP measured by PEP 
device  
Secondary: PEP 
technique  
 
 
 No follow up paper of results  
 
 
 
 
 
 
Ongoing studies  
Kiviet 201080  
 
 
Proposal.  
Conference 
abstract 
Children wCF  
200 patients 
 
Patient-accessed E-portal connected to 
Electronic Patient Dossier 
 
No comparator 
 
  
 Study not running yet 
 
 
Hind 201748,81  
 
   
 
 
 
 
 
 
 
RCT  
Conference 
abstract  
And protocol  
 
 
 
 
 
 
PwCF (6+ years) 
64 patients 
 
 
 
 
 
 
 
 
Information on adherence using a chipped 
nebuliser with software platform 
(CFHealthHub). Web-based with strategies 
to empower self-management delivered 
online and in six face-to-face/telephone 
sessions over 5 months 
 
 
 
 
Usual care 
 
 
 
 
 
 
 
 
 
Primary: Number of PE 
Secondary: knowledge, 
skills and self-
management (PAM-13), 
life chaos, generic health 
status, habit based 
behavioural patterns, 
QoL, HADS, adherence, 
medication beliefs, 
behaviour 
Feasibility study completed, RCT in 
progress.  
 
 
 
 
 
 
 
 
Mcllwaine 
201649 
 
 
 
 
Non-randomised 
interventional 
study 
Protocol 
 
 
PwCF (6 - 12 years) 
20 patients 
 
 
 
 
First 4 months: adherence measured via 
digital manometer attached to PEP devices 
vs patients own self-reported adherence.  
Second 4 months: PEP device attached to 
video game 
 
No comparator  
 
 
 
 
 
Primary: adherence to 
therapy (electronic vs 
self-report).  
secondary: change in 
FEV1 from 1st and 2nd 4 
month block  
 Ongoing study  
 
 
 
 
 
NCT02700243 
201650  
RCT  
Protocol 
Adults wCF 
40 patients 
Interact: given Fitbit exercise trackerTM and 
are followed over the course of one year, 
completing surveys and exercise tests 
 
Usual Care Graded exercise test; 
HAES,  FEV1 change from 
baseline; FEF25-75; PE 
requiring IV antibiotics; 
CFQ-R; use of social 
media; Depression scale 
Ongoing study  
ACTRN12617-
001009303  
201784   
RCT  
Protocol 
PwCF  
(12-24 years) 
inpatients 
Recruiting target 
150 patients 
Online programme (ActivOnline) + usual 
care. Participants record their daily physical 
activity and exercise using online portal. 
Patients set goals, record physical activity 
using a pedometer (or other device) with 
data displayed graphically so participants 
can see their progress. Facility to message 
researchers and other participants.  
Usual care: 
given details of 
online 
information 
website on 
physical activity 
Change in physical 
activity participation; 
change in exercise 
capacity; FEV1; CFQ-R; 
HADS; PSQI; time to first 
hospital admission; 
change in depression 
scale; HAES; number of 
hospital inpatient days 
Currently recruiting  
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NCT03672058 
Cahalan 201852  
RCT 
Protocol 
Adults wCF  
61 patients 
Both groups have fitness tracker linked to 
online monitoring system Fitabase (24 
weeks). Personalised weekly text message 
on progress for 12 weeks, next 12 weeks no 
feedback. 
Fitabase and 
exercise 
tracker.  
FEV1, maximal aerobic 
power, FVC, grip 
strength; BMI; muscle 
mass; % body fat; CFQ-R; 
subjective: physical 
activity; sleep quality; 
SoB; activity level; 
exacerbation frequency 
Ongoing study  
 
Hebestreit 
201851   
RCT 
Protocol 
PwCF (>/= 12 years) 
and FEV1 >/= 35% 
292 patients 
Weekly exercise regime (30 minutes 
strength, 2 hours aerobic) with regular 
monitoring and encouragement. 
Incorporates questionnaire, pedometer and 
daily logs. Centralised team monitors logs 
and contacts if inactivity for >3 days.  
Instructed to 
keep physical 
activity 
constant over 
12 months 
Change in FEV1 over 6 
months; exercise 
capacity, physical 
activity, pulmonary 
function,  exacerbations, 
QoL, HADS, compliance 
Enrolment 2014 - 2018. No results yet. 
NCT02277860 
201440   
Single group 
intervention 
study  
Protocol 
PwCF age 
(19years+) with 
stable CF  
11 patients 
12 week exercise programme delivered 
using Nintendo Wii FitTM for ≥ 30 min, ≥3 
days/week with monthly phone calls 
(exercise counselling and motivation). 
Further 12 weeks using the Wii but without 
supervision.  
No comparator Primary: peak oxygen 
consumption VO2 peak.  
secondary: nasal 
potential difference, 
HRQoL, habitual activity 
level  
May 2015 - Dec 2017  
ISRCTN51624752 
201853  
Intervention 
study  
pWCF (6-16 years) 
160 patients 
Project Fizzyo: Daily use of FitBit exercise 
trackerTM and electronic chipped sensor for 
use with ACT devices.  Data sent 
automatically when syncronised to a tablet 
device. Games also built into ACT devices 
and used at specific intervals in the study. 
Exercise test, spirometry and questionnaires 
completed at 3 time points.  
No comparator Primary: adherence to 
ACT. Physical activity. 
Secondary: types of 
physiotherapy, details of 
ACT, QoL, physical 
activity (steps and heart 
rate by Fitbit), lung 
function, exercise 
capacity  
Data collection over 16 months 
Ongoing 
Digital technology used for self-management 
 
Education  
NCT00185549 
200556  
 
 
 
 
 
RCT  
Protocol 
 
 
 
 
 
PwCF (1 month - 21 
years)   
60 patients 
 
 
 
 
Internet Access to the program CF.DOC. Aim 
to log on once a month and asked to set 
treatment goals and health measures. 
Program provides virtual visits, a personal 
health record, messaging with clinicians and 
several tools for monitoring self-care 
behaviours 
Usual care 
 
 
 
 
 
 
Primary outcome: 
improved nutritional 
status, improved CF QoL  
Secondary outcome: 
phone utilisation and 
analysis of program  
 
No results available - completed sept 
2005 
 
 
 
 
 
Grade: Low  
Although there were four 
studies for this outcome, 
only one was a completed 
RCT. The descriptive study 
had no comparator and the 
other RCT was only 
presented as a protocol 
with no results available 
despite study completion.  
Duff 200655  
 
 
 
Descriptive  
Full text 
 
 
Children wCF 
4 programs: 3-5yr, 
6-8yr, 9-11yr, 12yr+ 
 
An interactive CD-rom computer game 
“Betterland” with games, videos and 
activities focusing on different treatment 
aspects. 
No comparator 
 
 
 
Patient carer feedback 
 
 
 
Allows young people with CF to learn 
about their condition in an interactive 
and fun way. 
 
Stark 201658  
 
 
 
 
 
 
Technology 
assessment and 
Pilot study  
Full text 
 
 
 
Parents of PwCF (4-
9 years) BMI<50th 
centile  
10 patients 
 
 
 
BeInCharge: A web-based 7 module 
intervention program which included 
dietary education, a daily diet tracker App, 
personalised calorie intake goals and 
behaviour techniques.  
 
 
Standard care: 
usual care 
through CF 
centre.  
 
 
 
Weight change within 
each group; calorie 
intake; technical 
difficulties; adverse 
events.  
 
 
Designed and assessed usability of 
equipment. Children had an increased 
in weight from baseline to week 10. BIC 
by 0.67kg (p=0.04), standard 0.41kg 
(p=0.1). Weight gain not as good in BIC 
web compared to results seen 
previously in face-to-face.  
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Quittner 201357  
 
 
 
 
 
 
 
 
Controlled trial 
(randomisation 
unclear)  
Conference 
abstract 
 
 
 
 
Adolescents and 
young adults wCF  
95 patients 
 
 
 
 
 
 
CFfoneTM: smartphone with access to 
CFfone website via smartphone or home 
computer.  Website contained educational 
materials, quizzes, inspirational stories of 
peer role models, and a “chat” function in 
which they could post messages or 
communicate with peers 
 
 
Educational 
website for 
PwCF  
 
 
 
 
 
 
Knowledge of disease 
management; perceived 
adolescent social 
support, HADS; CFQ-R 
(treatment burden, 
social functioning, 
respiratory symptoms), 
adherence  
(Pharmacy refill data) 
Increased knowledge of disease 
management and social functioning at 6 
months but effect decreased 3 months 
post intervention. Improvement in the 
nutrition knowledge scale in 
intervention group at 3 months. No 
difference in HAD scores. Future 
analysis planned to assess adherence.  
 
Cummings 
201159 
 
 
 
 
 
 
RCT 
Full text 
 
 
 
 
 
 
PwCF with 
FEV1>35% 
20 patients  
 
 
 
 
 
Mentorship and self-monitoring via a mobile 
phone and web-based application.  
Intervention 1: access to a mentor guided 
self-efficacy program 
Intervention 2: as per Intervention1 plus the 
provision of a mobile phone and web-based 
App allowing participants to monitor their 
daily symptoms and QoL. 
Usual care 
 
 
 
 
 
 
 
Primary: health status, 
self efficacy, FEV1 and 
FVC. experiences of 
participants in study i.e. 
improving self-
management behaviour 
and QoL 
 
PwCF are confident to use ICT devices 
for self-monitoring. Both intervention 
groups had significant increase in self 
efficacy sustained at 12 months 
however was similar within both 
intervention groups, with mobile use 
reduced overtime.  
 
Grade: Very Low  
 
These were three small 
studies, one of which had 
no comparator group. The 
results from the White 
study were preliminary 
results only. 
Porco 201860   Intervention 
study 
Conference 
abstract 
PwCF 
15 patients 
Attain Health: Online weekly virtual 
meetings with Performance Coach and 
Integrative Health, group coaching sessions 
and educational webinars.  
No comparator  FEV1; BMI Mean increase in FEV1 was 3.3% (-2% to 
15%) over 3 months. Improved BMI 
10/15. 2 met a weight loss goal.  
White 201661,62 
 
 
 
 
 
 
 
RCT  
Protocol and 
conference 
abstract 
 
 
 
 
PwCF (16 – 60 
years)  
Target of 100 
patients 
 
 
 
 
Web based adherence intervention. 
Participants and clinicians jointly identify 1-3 
treatment areas to focus on to improve 
adherence. 6 interactive online modules on 
nutrition, PERT, vitamins, liver and 
respiratory disease and  antibiotics with 
incorporated interactive  materials and 
patient videos 
Usual care: 
information via 
fact sheets, 
discussion, and 
clinician 
explanation 
 
 
Primary: Changes in 
adherence: pharmacy 
refill, self-reporting  
secondary: BMI, weight, 
height, vitamin levels, 
lung function, IV abx 
days, QoL and 
knowledge. (at 1 year) 
Intervention group showed significant 
improvement in BMI, vitamin ADE 
levels. No difference in the rate of FEV1 
decline. No results reported on 
adherence but awaiting full analysis.  
 
 
 
Ongoing studies using education  
Lang 201964  
 
 
 
 
 
 
 
RCT  
Protocol 
 
 
 
 
 
 
PwCF (8-18 years) 
110 patients 
 
 
 
 
 
 
CyFiT: wrist worn activity tracker to record 
health information, and telehealth 
outpatient physiotherapy with real-time 
image/video sharing, features such as a 
whiteboard for drawing diagrams, 
measurement tools for physiotherapy and 
videoconferencing to delivery group based 
sessions.  CyFIT in addition to usual care.  
Usual care: 
outpatient 
physiotherapy 
(face to face, 
telephone 
and/or 
standard 
telehealth).  
Primary: pulmonary 
outcome; QoL  
Secondary: quality of 
care, cost effectiveness, 
participation in activities 
outside school, cough 
and activity, medical 
shuttle test 
No results published yet  
 
 
 
 
 
 
 
 
NCT03637504, 
201865   
 
 
 
 
 
 
RCT  
Protocol 
 
 
 
 
 
 
PwCF (12 years+)  
105 patients 
 
 
 
 
 
 
Web based medication management App 
[MedActionPlanTM (MAP) to encourage self-
management, education and adherence. 
Adherence measured by eTrack nebulisers 
and AdhereTech pill bottlesTM 
 
 
 
Usual care  
 
 
 
 
 
 
 
Feasibility and 
acceptability. Change in 
knowledge of disease 
management; CF 
medication beliefs; 
adherence; CF 
medication 
questionnaire  
Study in progress: start 2018. 
Completion 2021.  
 
 
 
 
 
 
NCT03139266 
201763 
 
 
 
 
 
RCT  
Protocol 
 
 
 
 
 
PwCF (13+ years), 
score GAD-7 and/or 
a 5-19 PHQ-10     
70 patients  
 
 
 
Project UPLIFT: Group web-based 
intervention comprised eight hour-long 
sessions aim to increase knowledge about 
depression, CF, cognitive behavioural 
therapy (CBT), and mindfulness and skills 
related to CBT, mindfulness and relaxation 
techniques with homework. 
Usual care: seek 
support from 
mental health 
services  
 
 
 
Primary: anxiety and 
depression symptoms 
Secondary: QoL, 
satisfaction with life, 
adherence, self-efficacy, 
knowledge and self-
Ongoing - to be completed May 2019.  
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   management of anxiety 
and depression 
Digital technology for self-management of treatments  
Breeding 201667   
 
 
 
 
Cohort study 
Conference 
abstract  
 
 
Adults wCF with 
pancreatic 
insufficiency  
5 patients 
 
Smartphone App to calculate PERT needed, 
used for 7 days with symptom questionnaire 
pre and post App use.  
 
 
No comparator 
 
 
 
 
GI symptoms  
 
 
 
 
Interim results: 1 patient completed the 
study at time of abstract. 100% 
reduction in symptoms. 47% reduction 
in bowel movements. Improved weight 
gain. No follow up publications 
Ongoing trials.  
Calvo-Lerma 
201768  
 
 
RCT  
Protocol 
 
 
PwCF (1-17 years) 
200 patients 
 
 
MyCyFAPP Project: Smartphone App to self-
manage nutrition and PERT. Able to be 
viewed by clinicians - alerts to patients and 
teams if not meeting targets.  
Not described 
 
 
 
QoL; nutritional status; 
healthcare usage 
 
 
The protocol is for design, development 
and implementation of the app 
including a multicentre RCT 
 
The use of social media for self-management in cystic fibrosis  
Kirk 201669  
 
 
 
 
 
 
 
 
 
Online 
ethnographical 
study  
Full text 
 
 
 
 
 
 
PwCF and parents of 
PwCF  
279 patients 
 
 
 
 
 
 
 
Review of message boards on a charity 
website online forum for young people and 
parents over a 4 month period. discussion 
threads downloaded for analysis 
 
 
 
 
 
 
No comparator 
 
 
 
 
 
 
 
 
 
To explore how online 
peer support is used to 
support self-care in CF 
 
 
 
 
 
 
 
Online support groups supplement 
professional support in relation to self-
management and self esteem. Used to 
share experiences, strategies for living 
with CF, emotional support and social 
networking.  
 
 
 
 
Grade: Very Low  
 
Although the ethnographic 
study had a large number of 
participants (n = 279), there 
was no comparator group 
and so it is unclear whether 
the effects seen were due 
to the intervention or other 
factors. 
Abbreviations: Adaptive Aerosol Delivery (AAD), Airway Clearance Techniques (ACTs),  Antibiotics (Abx),  Be In Charge (BIC), Body Mass Index (BMI), Cognitive Behavioural Therapy (CBT), Confidence Interval (CI), Cystic Fibrosis 
Respiratory Symptom Diary (CFRSD), Cystic Fibrosis Questionnaire-Revised (CFQ-R), Early Intervention (EI), early Intervention in Cystic Fibrosis (eICE), Forced Expiratory Flow 25-75% (FEF25-75), Forced Expiratory Volume in one second 
(FEV1), Forced Vital Capacity (FVC), Habitual activity estimation scale (HAES), Health related quality of life (HRQoL), High Frequency Chest Wall Compression (HFCWC) Hospital Anxiety and Depression Scale (HADS), Intravenous (IV), 
Modified Shuttle Walk Test (MSWT), Pancreatic Enzyme Replacement Therapy (PERT), People with Cystic Fibrosis (PwCF), Pittsburgh sleep quality index (PSQI), Positive Expiratory Pressure (PEP), Pulmonary exacerbation (PE), 
Pulmonary Function Tests (PFTs), Personal Trainer (PT), Randomised Control Trial (RCT), Respiratory Symptom Score (RSS), Shortness of Breath (SoB), Six Minute Stepper Test (6MST), Submaximal Graded exercise tolerance test (GXT), 
Target Inhalation Mode (TIM), Telemedicine (TM), Tidal Breathing Mode (TBM), Visual analogue scale (VAS) 
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